* parts 1 and 2: * recovered from confirmed covid-19 disease or asymptomatic infection * prior history of a positive sars-cov-2 serology test * history of convalescent covid-19 plasma treatment * participation in a previous sars-cov-2 vaccine trial or received an approved sars-cov-2 vaccine * previous receipt of sar-cov-2-specific monoclonal antibodies * have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study

* parts 1 and 2: * recovered from confirmed covid-19 disease or asymptomatic infection * prior history of a positive sars-cov-2 serology test * history of convalescent covid-19 plasma treatment * participation in a previous sars-cov-2 vaccine trial or received an approved sars-cov-2 vaccine * previous receipt of sar-cov-2-specific monoclonal antibodies * have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study

- parts 1 and 2: - recovered from confirmed covid-19 disease or asymptomatic infection - prior history of a positive sars-cov-2 serology test - history of convalescent covid-19 plasma treatment - participation in a previous sars-cov-2 vaccine trial or received an approved sars-cov-2 vaccine - previous receipt of sar-cov-2-specific monoclonal antibodies - have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study

- parts 1 and 2: - recovered from confirmed covid-19 disease or asymptomatic infection - prior history of a positive sars-cov-2 serology test - history of convalescent covid-19 plasma treatment - participation in a previous sars-cov-2 vaccine trial or received an approved sars-cov-2 vaccine - previous receipt of sar-cov-2-specific monoclonal antibodies - have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study

- recovered from confirmed covid-19 disease or asymptomatic infection - a prior history of a positive sars-cov-2 serology test - a history of convalescent covid-19 plasma treatment - participation in a previous sars-cov-2 vaccine trial or received an approved sars-cov-2 vaccine - previous receipt of sar-cov-2-specific monoclonal antibodies - have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study

- recovered from confirmed covid-19 disease or asymptomatic infection - a prior history of a positive sars-cov-2 serology test - a history of convalescent covid-19 plasma treatment - participation in a previous sars-cov-2 vaccine trial or received an approved sars-cov-2 vaccine - previous receipt of sar-cov-2-specific monoclonal antibodies - have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study

- recovered from confirmed covid-19 disease - a prior history of a positive sars-cov-2 serology test - a history of convalescent covid-19 plasma treatment - participation in a previous sars-cov-2 vaccine trial - previous receipt of sar-cov-2-specific monoclonal antibodies - have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study

- recovered from confirmed covid-19 disease - a prior history of a positive sars-cov-2 serology test - a history of convalescent covid-19 plasma treatment - participation in a previous sars-cov-2 vaccine trial - previous receipt of sar-cov-2-specific monoclonal antibodies - have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study